We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


IBD Gene Study May Help Improve Treatment

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Researchers at the Wellcome Trust Sanger Institute have narrowed down the list of specific genes responsible for Inflammatory Bowel Disease (IBD). The results could help to identify new drug targets and increase the effectiveness of existing treatments.

More than 300,000 people in the UK have IBD, a debilitating disease in which the body’s own immune system attacks parts of the digestive tract. The exact causes of the disease are unclear, and there is currently no cure.

How the research was done

Scientists at Sanger examined the genome of 67,852 people.

They then used three statistical methods to zoom in on variations in the genome which are actively implicated in the disease. Of the regions of the genome associated with IBD they studied, 18 could be pin-pointed to a single genetic variant.

Previous research had analysed the genomes of people with IBD and found hundreds of genetic variants that could be linked. But the researchers had been unable to specify the exact genes involved.

What the research found

This new research has produced a high-resolution map of the disease. It allows scientists to separate the genetic variants into those that directly influence IBD and those that just happen to be located near each other in the genome.

Dr Jeffrey Barrett, joint lead author from the Wellcome Trust Sanger Institute, says: "We have taken the biggest ever data set for IBD and applied careful statistics to narrow down to the individual genetic variants involved. Now we have a clearer picture of which genes do and do not play a role in the disease. We are zooming in on the genetic culprits of IBD."

This article has been republished from materials provided by Wellcome Trust Sanger Institute. Note: material may have been edited for length and content. For further information, please contact the cited source.


Hailiang Huang, Ming Fang, Luke Jostins, Maša Umićević Mirkov, Gabrielle Boucher, Carl A. Anderson, Vibeke Andersen, Isabelle Cleynen, Adrian Cortes, François Crins, Mauro D’Amato, Valérie Deffontaine, Julia Dmitrieva, Elisa Docampo, Mahmoud Elansary, Kyle Kai-How Farh, Andre Franke, Ann-Stephan Gori, Philippe Goyette, Jonas Halfvarson, Talin Haritunians, Jo Knight, Ian C. Lawrance, Charlie W. Lees, Edouard Louis, Rob Mariman, Theo Meuwissen, Myriam Mni, Yukihide Momozawa, Miles Parkes, Sarah L. Spain, Emilie Théâtre, Gosia Trynka, Jack Satsangi, Suzanne van Sommeren, Severine Vermeire, Ramnik J. Xavier, Rinse K. Weersma, Richard H. Duerr, Christopher G. Mathew, John D. Rioux, Dermot P. B. McGovern, Judy H. Cho, Michel Georges, Mark J. Daly, Jeffrey C. Barrett. Fine-mapping inflammatory bowel disease loci to single-variant resolution. Nature, 2017; DOI: 10.1038/nature22969